Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 6/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 13/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944865 | 1.00 | LIPE (0.56) | LIPEKCNJ1KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1943405 | 0.88 | LIPE (0.52) | LIPEKCNJ1KCNH2 | |
| SCHEMBL1943392 | 0.88 | LIPE (0.52) | LIPEKCNJ1KCNH2 | |
| SCHEMBL1944403 | 0.84 | LIPE (0.56) | LIPEKCNJ1KCNH2 | |
| SCHEMBL1947265 | 0.84 | LIPE (0.56) | LIPEKCNJ1KCNH2 | |
| SCHEMBL20814271 | 0.80 | CYP3A4 (0.38) | LIPEKCNJ1KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1944235 | 0.80 | LIPE (0.64) | LIPEKCNJ1KCNH2 | |
| SCHEMBL1944523 | 0.78 | LIPE (0.47) | LIPEKCNJ1KCNH2 | |
| SCHEMBL1959837 | 0.78 | LIPE (0.66) | LIPE | |
| SCHEMBL1946544 | 0.78 | LIPE (0.66) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A1 | LIPE 4817/4885KCNJ1 1276/4885KCNH2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.